Structural and functional properties of prefibrillar α-synuclein oligomers

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Pieri, Laura ^a   Madiona, Karine ^a   Melki, Ronald ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MACROMOLECULE;

CELL SURVIVAL; HUMAN; MACROMOLECULE; METABOLISM; MICROSCOPY; NERVE CELL; PHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; TOXICITY; TUMOR CELL LINE; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MACROMOLECULAR SUBSTANCES; MICROSCOPY; NEURONS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION;

EID: 84963812933     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24526     Document Type: Article

References (64)

1. McCann, H., Stevens, C. H., Cartwright, H. & Halliday, G. M. ?-Synucleinopathy phenotypes. Parkinsonism Relat. Disord. 20, S62-67 (2014).
2. Spillantini, M. G. et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208 (1998).
3. Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of ?-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48 (2013).
4. Crowther, R. A., Jakes, R., Spillantini, M. G. & Goedert, M. Synthetic filaments assembled from C-terminally truncated alphasynuclein. FEBS Lett. 436, 309-312 (1998).
5. Lashuel, H. A. et al. Alpha-synuclein, especially the Parkinson's disease-Associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102 (2002).
6. Goldberg, M. S. & Lansbury P. T., Jr. Is there a cause-And-effect relationship between ?-synuclein fibrillization and Parkinson's disease? Nat. Cell. Biol. 2, E115-E119 (2000).
7. Pieri, L., Madiona, K., Bousset, L. & Melki, R. Fibrillar ?-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 102, 2894-2905 (2012).
8. Shrivastava, A. N. et al. ?-synuclein assemblies sequester neuronal ? 3-Na+/K+-ATPase and impair Na+ gradient. EMBO J. 34, 2408-2423 (2015).
9. Pieri, L. et al. Cellular response of human neuroblastoma cells to ?-synuclein fibrils, the main constituent of Lewy bodies. Biochim. Biophys. Acta 1860, 8-19 (2015).
10. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of ?-synuclein. Proc. Natl. Acad. Sci. USA 106, 13010-13015 (2009).
11. Hansen, C. et al. ?-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715-725 (2011).
12. Brettschneider, J., Del Tredici, K., Lee, V. M. & Trojanowski, J. Q. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci. 16, 109-120 (2015).
13. Bousset, L. et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4, 2575 (2013).
14. Luk, K. C. et al. Pathological ?-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012).
15. Mougenot, A. L. et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging. 33, 2225-2228 (2012).
16. Rey, N. L., Petit, G. H., Bousset, L., Melki, R. & Brundin, P. Transfer of human ?-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol. 126, 555-573 (2013).
17. Sacino, A. N. et al. Intramuscular injection of ?-synuclein induces CNS ?-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. USA 111, 10732-10737 (2014).
18. Holmqvist, S. et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805-820 (2014).
19. Peelaerts, W. et al. ?-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340-344 (2015).
20. Danzer, K. M. et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220-9232 (2007).
21. Danzer, K. M., Krebs, S. K., Wolff, M., Birk, G. & Hengerer, B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J. Neurochem. 111, 192-203 (2009).
22. Zhang, N. Y., Tang, Z. & Liu, C. W. alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J. Biol. Chem. 283, 20288-20298 (2008).
23. Hinault, M. P. et al. Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J. Biol. Chem. 285, 38173-38182 (2010).
24. Paslawski, W., Mysling, S., Thomsen, K., Jørgensen, T. J. & Otzen, D. E. Co-existence of two different ?-synuclein oligomers with different core structures determined by hydrogen/deuterium exchange mass spectrometry. Angew. Chem. Int. Ed. Engl. 53, 7560-7563 (2014).
25. Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of ?-synuclein. Cell 149, 1048-1059 (2012).
26. Qin, Z. et al. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 282, 5862-5870 (2007).
27. Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566 (2008).
28. Zhou, W. et al. Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim. Biophys. Acta. 1802, 322-330 (2010).
29. Uversky, V. N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21, 211-234 (2003).
30. Cappai, R. et al. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19, 1377-1379 (2005).
31. Mazzulli, J. R. et al. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068-10078 (2006).
32. Lee, H. J. et al. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp. Mol. Med. 43, 216-222 (2011).
33. Leong, S. L., Cappai, R., Barnham, K. J. & Pham, C. L. Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem. Res. 34, 1838-1846 (2009).
34. Andreasen, M., Lorenzen, N. & Otzen, D. Interactions between misfolded protein oligomers and membranes: A central topic in neurodegenerative diseases? Biochim. Biophys. Acta 1848, 1897-1907 (2015).
35. Migneault, I., Dartiguenave, C., Bertrand, M. J. & Waldron, K. C. Glutaraldehyde: behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. Biotechniques 37, 790-796, 798-802 (2004).
36. Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys. J. 78, 1606-1619 (2000).
37. Schuck, P., Perugini, M. A., Gonzales, N. R., Howlett, G. J. & Schubert, D. Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. Biophys. J. 82, 1096-1111 (2002).
38. Planchard, M. S., Exley, S. E., Morgan, S. E. & Rangachari, V. Dopamine-induced ?-synuclein oligomers show self-And crosspropagation properties. Protein Sci. 23, 1369-1379 (2014).
39. Freundt, E. C. et al. Neuron-to-neuron transmission of ?-synuclein fibrils through axonal transport. Ann. Neurol. 72, 517-524 (2012).
40. Brahic, M., Bousset, L., Bieri, G., Melki, R. & Gitler, A. D. Axonal transport and secretion of fibrillar forms of ?-synuclein, A? 42 peptide and HTTExon 1. Acta Neuropathol. doi: 10.1007/s00401-016-1538-0 (2016).
41. El-Agnaf, O. M. et al. Detection of oligomeric forms of ?-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419-425 (2006).
42. Tokuda, T. et al. Detection of elevated levels of ?-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1772 (2010).
43. Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular ?-synuclein-A novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92-98 (2014).
44. Conway, K. A. et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97, 571-576 (2000).
45. Caughey, B. & Lansbury, P. T., Jr. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
46. Winner, B. et al. In vivo demonstration that ?-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 4194-4199 (2011).
47. Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M. & Lang, A. E. ?-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 73, 155-169 (2013).
48. Volles M. J. et al. Vesicle permeabilization by protofibrillar ?-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819 (2001).
49. Lorenzen, N. et al. The role of stable ?-synuclein oligomers in the molecular events underlying amyloid formation. J. Am. Chem. Soc. 136, 3859-3868 (2014).
50. Karpinar, D. P. et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28, 3256-3268 (2009).
51. Taschenberger, G. et al. Aggregation of ? Synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 123, 671-683 (2012).
52. El-Agnaf, O. M. et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440, 71-75 (1998).
53. Bieschke, J. et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. USA 107, 7710-7715 (2010).
54. Osterberg, V. R. et al. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of Parkinsonism. Cell Rep. 10, 1252-1260 (2015).
55. Gao, X. et al. Human Hsp70 Disaggregase Reverses Parkinson's-Linked ?-Synuclein Amyloid Fibrils. Mol. Cell. 59, 781-793 (2015).
56. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
57. Galvin, J. E. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol. 112, 115-126 (2006).
58. Xu, J. et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606 (2002).
59. Ito, S., Nakaso, K., Imamura, K., Takeshima, T. & Nakashima, K. Endogenous catecholamine enhances the dysfunction of unfolded protein response and alpha-synuclein oligomerization in PC12 cells overexpressing human alpha-synuclein. Neurosci. Res. 66, 124-130 (2010).
60. Yamakawa, K. et al. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. Biochem. Biophys. Res. Commun. 391, 129-134 (2010).
61. Ghee, M., Melki, R., Michot, N. & Mallet, J. PA700, the regulatory complex of the 26S proteasome, interferes with ?-synuclein assembly. FEBS J. 272, 4023-4033 (2005).
62. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63 (1983).
63. Shearman, M. S., Ragan, C. I. & Iversen L. L. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-Amyloid-mediated cell death. Proc. Natl. Acad. Sci. USA 91, 1470-1474 (1994).
64. Pemberton, S. et al. Hsc70 protein interaction with soluble and fibrillar alpha-synuclein. J. Biol. Chem. 286, 34690-34699 (2011).